Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vimseltinib in Advanced Tumors and Tenosynovial Giant Cell Tumor
NCT03069469Phase 2Active, not recruiting
- Sponsor
- Deciphera Pharmaceuticals
- Start
- Feb 2017
- Primary completion
- Aug 2028
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 9
01
Overview
A Phase 2 trial of vimseltinib in advanced malignant solid tumor, tenosynovial giant cell tumor (TGCT), sponsored by Deciphera Pharmaceuticals. Started Feb 2017; status: active, not recruiting.
02
Drugs
vimseltinib
03
Conditions
advanced malignant solid tumortenosynovial giant cell tumor (TGCT)
Beyond the preview
Go deeper on NCT03069469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03069469.